HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J results

This article was originally published in The Rose Sheet

Executive Summary

Adult skin and hair care business grew 14% in the third quarter, including approximately 1% positive currency impact, Johnson & Johnson says during Oct. 18 earnings call. In the U.S., "solid performances from our Neutrogena and RoC brands complemented by very strong results with Aveeno were major drivers of growth," firm notes, adding growth drivers outside the U.S. wereJohnson's adult products, Neutrogena and Clean & Clear anti-acne brand. Baby and kids' care sales grew 7%. Johnson's Bathtime Buddies led 3% revenue growth in the U.S., and Softlotion products and Bathtime Buddies drove 8% growth outside the U.S. Worldwide consumer product sales were $2.23 bil., up 10.2% including a positive currency impact of 1.7%, and U.S. sales in the segment increased 5.1% to $1.08 bil...

You may also be interested in...

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.

Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts